477 related articles for article (PubMed ID: 27019408)
21. TMEM175 deficiency impairs lysosomal and mitochondrial function and increases α-synuclein aggregation.
Jinn S; Drolet RE; Cramer PE; Wong AH; Toolan DM; Gretzula CA; Voleti B; Vassileva G; Disa J; Tadin-Strapps M; Stone DJ
Proc Natl Acad Sci U S A; 2017 Feb; 114(9):2389-2394. PubMed ID: 28193887
[TBL] [Abstract][Full Text] [Related]
22. Neuronopathic GBA1L444P Mutation Accelerates Glucosylsphingosine Levels and Formation of Hippocampal Alpha-Synuclein Inclusions.
Mahoney-Crane CL; Viswanathan M; Russell D; Curtiss RAC; Freire J; Bobba SS; Coyle SD; Kandebo M; Yao L; Wan BL; Hatcher NG; Smith SM; Marcus JN; Volpicelli-Daley LA
J Neurosci; 2023 Jan; 43(3):501-521. PubMed ID: 36639889
[TBL] [Abstract][Full Text] [Related]
23. Mutant GBA1 expression and synucleinopathy risk: first insights from cellular and mouse models.
Sardi SP; Singh P; Cheng SH; Shihabuddin LS; Schlossmacher MG
Neurodegener Dis; 2012; 10(1-4):195-202. PubMed ID: 22327140
[TBL] [Abstract][Full Text] [Related]
24. Glucocerebrosidase reduces the spread of protein aggregation in a Drosophila melanogaster model of neurodegeneration by regulating proteins trafficked by extracellular vesicles.
Jewett KA; Thomas RE; Phan CQ; Lin B; Milstein G; Yu S; Bettcher LF; Neto FC; Djukovic D; Raftery D; Pallanck LJ; Davis MY
PLoS Genet; 2021 Feb; 17(2):e1008859. PubMed ID: 33539341
[TBL] [Abstract][Full Text] [Related]
25. Impact of Gba2 on neuronopathic Gaucher's disease and α-synuclein accumulation in medaka (Oryzias latipes).
Nakanishi E; Uemura N; Akiyama H; Kinoshita M; Masanori S; Taruno Y; Yamakado H; Matsuzawa SI; Takeda S; Hirabayashi Y; Takahashi R
Mol Brain; 2021 May; 14(1):80. PubMed ID: 33971917
[TBL] [Abstract][Full Text] [Related]
26. Glucocerebrosidase modulates cognitive and motor activities in murine models of Parkinson's disease.
Rockenstein E; Clarke J; Viel C; Panarello N; Treleaven CM; Kim C; Spencer B; Adame A; Park H; Dodge JC; Cheng SH; Shihabuddin LS; Masliah E; Sardi SP
Hum Mol Genet; 2016 Jul; 25(13):2645-2660. PubMed ID: 27126635
[TBL] [Abstract][Full Text] [Related]
27. Glucocerebrosidase activity, cathepsin D and monomeric α-synuclein interactions in a stem cell derived neuronal model of a PD associated GBA1 mutation.
Yang SY; Gegg M; Chau D; Schapira A
Neurobiol Dis; 2020 Feb; 134():104620. PubMed ID: 31634558
[TBL] [Abstract][Full Text] [Related]
28. Glucocerebrosidase is present in α-synuclein inclusions in Lewy body disorders.
Goker-Alpan O; Stubblefield BK; Giasson BI; Sidransky E
Acta Neuropathol; 2010 Nov; 120(5):641-9. PubMed ID: 20838799
[TBL] [Abstract][Full Text] [Related]
29. Activation of β-Glucocerebrosidase Reduces Pathological α-Synuclein and Restores Lysosomal Function in Parkinson's Patient Midbrain Neurons.
Mazzulli JR; Zunke F; Tsunemi T; Toker NJ; Jeon S; Burbulla LF; Patnaik S; Sidransky E; Marugan JJ; Sue CM; Krainc D
J Neurosci; 2016 Jul; 36(29):7693-706. PubMed ID: 27445146
[TBL] [Abstract][Full Text] [Related]
30. Involvement of Gaucher Disease Mutations in Parkinson Disease.
Vilageliu L; Grinberg D
Curr Protein Pept Sci; 2017; 18(7):758-764. PubMed ID: 26965692
[TBL] [Abstract][Full Text] [Related]
31.
Granek Z; Barczuk J; Siwecka N; Rozpędek-Kamińska W; Kucharska E; Majsterek I
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768367
[TBL] [Abstract][Full Text] [Related]
32. Glucocerebrosidase deficiency promotes release of α-synuclein fibrils from cultured neurons.
Gegg ME; Verona G; Schapira AHV
Hum Mol Genet; 2020 Jun; 29(10):1716-1728. PubMed ID: 32391886
[TBL] [Abstract][Full Text] [Related]
33. CNS expression of glucocerebrosidase corrects alpha-synuclein pathology and memory in a mouse model of Gaucher-related synucleinopathy.
Sardi SP; Clarke J; Kinnecom C; Tamsett TJ; Li L; Stanek LM; Passini MA; Grabowski GA; Schlossmacher MG; Sidman RL; Cheng SH; Shihabuddin LS
Proc Natl Acad Sci U S A; 2011 Jul; 108(29):12101-6. PubMed ID: 21730160
[TBL] [Abstract][Full Text] [Related]
34. Path mediation analysis reveals GBA impacts Lewy body disease status by increasing α-synuclein levels.
Gündner AL; Duran-Pacheco G; Zimmermann S; Ruf I; Moors T; Baumann K; Jagasia R; van de Berg WDJ; Kremer T
Neurobiol Dis; 2019 Jan; 121():205-213. PubMed ID: 30236861
[TBL] [Abstract][Full Text] [Related]
35. Can GBA1-Associated Parkinson Disease Be Modeled in the Mouse?
Farfel-Becker T; Do J; Tayebi N; Sidransky E
Trends Neurosci; 2019 Sep; 42(9):631-643. PubMed ID: 31288942
[TBL] [Abstract][Full Text] [Related]
36. Glucocerebrosidase Gene Therapy Induces Alpha-Synuclein Clearance and Neuroprotection of Midbrain Dopaminergic Neurons in Mice and Macaques.
Sucunza D; Rico AJ; Roda E; Collantes M; González-Aseguinolaza G; Rodríguez-Pérez AI; Peñuelas I; Vázquez A; Labandeira-García JL; Broccoli V; Lanciego JL
Int J Mol Sci; 2021 May; 22(9):. PubMed ID: 34062940
[TBL] [Abstract][Full Text] [Related]
37. Glucocerebrosidase gene therapy prevents α-synucleinopathy of midbrain dopamine neurons.
Rocha EM; Smith GA; Park E; Cao H; Brown E; Hayes MA; Beagan J; McLean JR; Izen SC; Perez-Torres E; Hallett PJ; Isacson O
Neurobiol Dis; 2015 Oct; 82():495-503. PubMed ID: 26392287
[TBL] [Abstract][Full Text] [Related]
38. Glucocerebrosidase, a new player changing the old rules in Lewy body diseases.
Yang NY; Lee YN; Lee HJ; Kim YS; Lee SJ
Biol Chem; 2013 Jul; 394(7):807-18. PubMed ID: 23435096
[TBL] [Abstract][Full Text] [Related]
39. Development of targeted therapies for Parkinson's disease and related synucleinopathies.
Sybertz E; Krainc D
J Lipid Res; 2014 Oct; 55(10):1996-2003. PubMed ID: 24668939
[TBL] [Abstract][Full Text] [Related]
40. Cross-talks among GBA mutations, glucocerebrosidase, and α-synuclein in GBA-associated Parkinson's disease and their targeted therapeutic approaches: a comprehensive review.
Behl T; Kaur G; Fratila O; Buhas C; Judea-Pusta CT; Negrut N; Bustea C; Bungau S
Transl Neurodegener; 2021 Jan; 10(1):4. PubMed ID: 33446243
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
